Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Next Previous
X
Search
Trial Profile

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonapanitase (Primary)
  • Indications Vascular disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Proteon Therapeutics

    • Most Recent Events

    • 22 May 2015 According to a Proteon Therapeutics media release, 3-year long-term follow-up data from this study will be presented at the 52nd ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) Congress 2015.
    • 13 Apr 2015 Results presented at 9th Congress of the Vascular Access Society, as per Proteon Therapeutics.
    • 26 Mar 2015 According to a Proteon Therapeutics media release, data from the long-term analysis of this trial was presented at National Kidney Foundation's (NKF) 2015 Spring Clinical Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top